azathioprine has been researched along with Skin Diseases, Vascular in 3 studies
Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.
Skin Diseases, Vascular: Skin diseases affecting or involving the cutaneous blood vessels and generally manifested as inflammation, swelling, erythema, or necrosis in the affected area.
| Excerpt | Relevance | Reference |
|---|---|---|
| "ARAMIS is a multicenter, sequential, multiple assignment randomized trial with an enrichment design (SMARTER) aimed at comparing the efficacy of three drugs-azathioprine, colchicine, and dapsone-commonly used to treat various forms of isolated skin vasculitis." | 9.34 | Protocol for a randomized multicenter study for isolated skin vasculitis (ARAMIS) comparing the efficacy of three drugs: azathioprine, colchicine, and dapsone. ( Borchin, R; Grayson, PC; Krischer, JP; McAlear, CA; Merkel, PA; Micheletti, RG; Pagnoux, C; Tamura, RN, 2020) |
| "ARAMIS is a multicenter, sequential, multiple assignment randomized trial with an enrichment design (SMARTER) aimed at comparing the efficacy of three drugs-azathioprine, colchicine, and dapsone-commonly used to treat various forms of isolated skin vasculitis." | 5.34 | Protocol for a randomized multicenter study for isolated skin vasculitis (ARAMIS) comparing the efficacy of three drugs: azathioprine, colchicine, and dapsone. ( Borchin, R; Grayson, PC; Krischer, JP; McAlear, CA; Merkel, PA; Micheletti, RG; Pagnoux, C; Tamura, RN, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Micheletti, RG | 2 |
| Pagnoux, C | 2 |
| Tamura, RN | 1 |
| Grayson, PC | 1 |
| McAlear, CA | 1 |
| Borchin, R | 1 |
| Krischer, JP | 1 |
| Merkel, PA | 1 |
| Dhanjal, S | 1 |
| Saso, A | 1 |
| Eleftheriou, D | 1 |
| Laurent, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Multicenter Study for Isolated Skin Vasculitis[NCT02939573] | Phase 2 | 90 participants (Anticipated) | Interventional | 2017-01-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for azathioprine and Skin Diseases, Vascular
| Article | Year |
|---|---|
Management of cutaneous vasculitis.
Topics: Azathioprine; Colchicine; Consensus; Diagnosis, Differential; Drug Resistance; Glucocorticoids; Huma | 2020 |
1 trial available for azathioprine and Skin Diseases, Vascular
| Article | Year |
|---|---|
Protocol for a randomized multicenter study for isolated skin vasculitis (ARAMIS) comparing the efficacy of three drugs: azathioprine, colchicine, and dapsone.
Topics: Azathioprine; Colchicine; Cross-Over Studies; Dapsone; Drug Resistance; Humans; Multicenter Studies | 2020 |
1 other study available for azathioprine and Skin Diseases, Vascular
| Article | Year |
|---|---|
Necrotic cutaneous vasculitic skin lesions: a case of atypical Henoch-Schönlein purpura in a child with heterozygosity for factor V Leiden.
Topics: Aspirin; Azathioprine; Biopsy; Child, Preschool; Factor V; Humans; IgA Vasculitis; Immunosuppressive | 2017 |